EP1470249A2 - Effecteurs d'immunite innee - Google Patents

Effecteurs d'immunite innee

Info

Publication number
EP1470249A2
EP1470249A2 EP20020804139 EP02804139A EP1470249A2 EP 1470249 A2 EP1470249 A2 EP 1470249A2 EP 20020804139 EP20020804139 EP 20020804139 EP 02804139 A EP02804139 A EP 02804139A EP 1470249 A2 EP1470249 A2 EP 1470249A2
Authority
EP
European Patent Office
Prior art keywords
peptide
seq
expression
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP20020804139
Other languages
German (de)
English (en)
Inventor
Robert E. W. Hancock
B. Brett Finlay
Monisha Gough Scott
Dawn Bowdish
Carrie Melissa Rosenberger
Jon-Paul Steven Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of EP1470249A2 publication Critical patent/EP1470249A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates generally to peptides and specifically to peptides effective as therapeutics and for drug discovery related to pathologies resulting from microbial infections and for modulating innate immunity or anti-inflammatory activity.
  • Infectious diseases are the leading cause of death worldwide. According to a 1999 World Health Organization study, over 13 million people die from infectious diseases each year. Infectious diseases are the third leading cause of death in North America, accounting for 20% of deaths annually and increasing by 50% since 1980. The success of many medical and surgical treatments also hinges on the control of infectious diseases. The discovery and use of antibiotics has been one of the great achievements of modern medicine. Without antibiotics, physicians would be unable to perform complex surgery, chemotherapy or most medical interventions such as catheterization.
  • the innate immune system is a highly effective and evolved general defense system. Elements of innate immunity are always present at low levels and are activated very rapidly when stimulated. Stimulation can include interaction of bacterial signaling molecules with pattern recognition receptors on the surface of the body's cells or other mechanisms of disease. Every day, humans are exposed to tens of thousands of potential pathogenic microorganisms through the food and water we ingest, the air we breathe and the surfaces, pets and people that we touch. The innate immune system acts to prevent these pathogens from causing disease. The innate immune system differs from so-called adaptive immunity (which includes antibodies and antigen-specific B- and T-lymphocytes) because it is always present, effective immediately, and relatively non-specific for any given pathogen.
  • adaptive immunity which includes antibodies and antigen-specific B- and T-lymphocytes
  • the adaptive immune system requires amplification of specific recognition elements and thus takes days to weeks to respond. Even when adaptive immunity is pre-stimulated by vaccination, it may take three days or more to respond to a pathogen whereas innate immunity is immediately or rapidly (hours) available. Innate immunity involves a variety of effector functions including phagocytic cells, complement, etc, but is generally incompletely understood. Generally speaking many innate immune responses are "triggered” by the binding of microbial signaling molecules with pattern recognition receptors termed Toll-like receptors on the surface of host cells. Many of these effector functions are grouped together in the inflammatory response. However too severe an inflammatory response can result in responses that are harmful to the body, and in an extreme case sepsis and potentially death can occur.
  • Sepsis occurs in approximately 780,000 patients in North America annually. Sepsis may develop as a result of infections acquired in the community such as pneumonia, or it may be a complication of the treatment of trauma, cancer or major surgery. Severe sepsis occurs when the body is overwhelmed by the inflammatory response and body organs begin to fail. Up to 120,000 deaths occur annually in the United Stated due to sepsis. Sepsis may also involve pathogenic microorganisms or toxins in the blood (e.g., septicemia), which is a leading cause of death among humans. Gram-negative bacteria are the organisms most commonly associated with such diseases. However, gram-positive bacteria are an increasing cause of infections. Gram-negative and Gram-positive bacteria and their components can all cause sepsis.
  • TNF- ⁇ tumor necrosis factor-
  • LPS lipopolysaccharide
  • Gram-positive sepsis can be caused by the release of bacterial cell wall components such as lipoteichoic acid (LTA), peptidoglycan (PG), rhamnose-glucose polymers made by Streptococci, or capsular polysaccharides made by Staphylococci.
  • LTA lipoteichoic acid
  • PG peptidoglycan
  • CpG DNA unmethylated cytosine-guanosine dimers
  • Mammalian DNA contains CpG dinucleotides at a much lower frequency, often in a methylated form.
  • antibiotic treatment can also cause release of the bacterial cell wall components LPS and LTA and probably also bacterial DNA. This can then hinder recovery from infection or even cause sepsis.
  • Cationic peptides are being increasingly recognized as a form of defense against infection, although the major effects recognized in the scientific and patent literature are the antimicrobial effects (Hancock, R.E.W., and R. Lehrer. 1998. Cationic peptides: a new source of antibiotics. Trends in Biotechnology 16: 82-88.). Cationic peptides having antimicrobial activity have been isolated from a wide variety of organisms. In nature, such peptides provide a defense mechanism against microorganisms such as bacteria and yeast. Generally, these cationic peptides are thought to exert their antimicrobial activity on bacteria by interacting with the cytoplasmic membrane, and in most cases, forming channels or lesions.
  • cationic antimicrobial peptides include indolicidin, defensins, cecropins, and magainins.
  • Some cationic peptides have an affinity for binding bacterial products such as LPS and LTA. Such cationic peptides can suppress cytokine production in response to LPS, and to varying extents can prevent lethal shock. However it has not been proven as to whether such effects are due to binding of the peptides to LPS and LTA, or due to a direct interaction of the peptides with host cells. Cationic peptides are induced, in response to challenge by microbes or microbial signaling molecules like LPS, by a regulatory pathway similar to that used by the mammalian immune system (involving Toll like receptors and the transcription factor; NFKB). Cationic peptides therefore appear to have a key role in innate immunity.
  • Mutations that affect the induction of antibacterial peptides can reduce survival in response to bacterial challenge.
  • mutations of the Toll pathway oi Drosophila that lead to decreased antifungal peptide expression result in increased susceptibility to lethal fungal infections.
  • patients with specific granule deficiency syndrome, completely lacking in ⁇ -defensins suffer from frequent and severe bacterial infections.
  • Other evidence includes the inducibility of some peptides by infectious agents, and the very high concentrations that have been recorded at sites of inflammation.
  • Cationic peptides may also regulate cell migration, to promote the ability of leukocytes to combat bacterial infections.
  • HNP-1 and HNP-2 two human ⁇ - defensin peptides, HNP-1 and HNP-2, have been indicated to have direct chemotactic activity for murine and human T cells and monocytes, and human ⁇ -defensins appear to act as chemoattractants for immature dendritic cells and memory T cells through interaction with CCR6.
  • porcine cationic peptide, PR-39 was found to be chemotactic for neutrophils. It is unclear however as to whether peptides of different structures and compositions share these properties.
  • cathelicidin from humans LL-37
  • the single known cathelicidin from humans, LL-37 is produced by myeloid precursors, testis, human keratinocytes during inflammatory disorders and airway epithelium.
  • the characteristic feature of cathelicidin peptides is a high level of sequence identity at the N-terminus prepro regions termed the cathelin domain.
  • Cathelicidin peptides are stored as inactive propeptide precursors that, upon stimulation, are processed into active peptides.
  • the present invention is based on the seminal discovery that based on patterns of polynucleotide expression regulated by endotoxic lipopolysaccharide, lipoteichoic acid, CpG DNA, or other cellular components (e.g., microbes or their cellular components), and affected by cationic peptides, one can screen for novel compounds that block or reduce sepsis and/or inflammation in a subject. Further, based on the use of cationic peptides as a tool, one can identify selective enhancers of innate immunity that do not trigger the sepsis reaction and that can block/dampen inflammatory and/or septic responses.
  • a method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a cationic peptide includes contacting the polynucleotide or polynucleotides with one or more sepsis or inflammatory inducing agents and contacting the polynucleotide or polynucleotides with a cationic peptide either simultaneously or immediately thereafter.
  • Differences in expression are detected in the presence and absence of the cationic peptide, and a change in expression, either up- or down-regulation, is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing agent and inhibited by a cationic peptide.
  • the invention provides a polynucleotide or polynucleotides identified by the above method.
  • sepsis or inflammatory regulatory agents include LPS, LTA or CpG DNA or microbial components (or any combination thereof), or related agents.
  • the invention provides a method of identifying an agent that blocks sepsis or inflammation including combining a polynucleotide identified by the method set forth above with an agent wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulation in expression affects an inflammatory or septic response.
  • the invention provides a method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response by 1) contacting cells with LPS, LTA and/or CpG DNA in the presence or absence of a cationic peptide and 2) detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide.
  • the pattern obtained in the presence of the peptide represents inhibition of an inflammatory or septic response.
  • the pattern obtained in the presence of the peptide is compared to the pattern of a test compound to identify a compound that provides a similar pattern.
  • the invention provides a compound identified by the foregoing method.
  • the invention provides a method of identifying an agent that enhances innate immunity by contacting a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression of the polynucleotide in the absence of the agent and wherein the modulated expression results in enhancement of innate immunity.
  • the agent does not stimulate a sepsis reaction in a subject.
  • the agent increases the expression of an anti-inflammatory polynucleotide.
  • Exemplary, but non-limiting anti-inflammatory polynucleotides encode proteins such as IL-1 R antagonist homolog 1 (AI167887), IL-10 R beta (AA486393), IL-10 R alpha (U00672) TNF Receptor member IB (AA150416), TNF receptor member 5 (H98636), TNF receptor member lib (AA 194983), IK cytokine down-regulator of HLA II (R39227), TGF-B inducible early growth response 2 (AI473938), CD2 (AA927710), IL-19 (NM_013371) or IL-10 (M57627).
  • proteins such as IL-1 R antagonist homolog 1 (AI167887), IL-10 R beta (AA486393), IL-10 R alpha (U00672) TNF Receptor member IB (AA150416), TNF receptor member 5 (H98636), TNF receptor member lib (AA 194983), IK cytokine down-regulator of HLA II (R39
  • the agent decreases the expression of polynucleotides encoding proteasome subunits involved in NF- ⁇ B activation such as proteasome subunit 26S (NM_013371).
  • the agent may act as an antagonist of protein kinases.
  • the agent is a peptide selected from SEQ ID NO:4-54.
  • the invention provides a method of identifying a pattern of polynucleotide expression for identification of a compound that selectively enhances innate immunity.
  • the invention includes detecting a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide, wherein the pattern in the presence of the peptide represents stimulation of innate immunity; detecting a pattern of polynucleotide expression for cells contacted in the presence of a test compound, wherein a pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide, is indicative of a compound that enhances innate immunity. It is preferred that the compound does not stimulate a septic reaction in a subject.
  • the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 50, 51 and or 52, as compared to a non-infected subject. Also included is a polynucleotide expression pattern obtained by any of the methods described above.
  • a cationic peptide that is an antagonist of CXCR-4 is provided.
  • a method of identifying a cationic peptide that is an antagonist of CXCR-4 by contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis is provided. A decrease in chemotaxis in the presence of the test peptide is indicative of a peptide that is an antagonist of CXCR-4.
  • Cationic peptide also acts to reduce the expression of the SDF-1 receptor polynucleotide (NM_013371).
  • the compounds or agents of the invention include but are not limited to peptides, cationic peptides, peptidomimetics, chemical compounds, polypeptides, nucleic acid molecules and the like.
  • an isolated cationic peptide is represented by one of the following general formulas and the single letter amino acid code:
  • X,X 2 X 3 IX PX IPX5X 2 X ⁇ (SEQ ID NO: 4), where X, is one or two of R, L or K, X 2 is one of C, S or A, X 3 is one of R or P, X 4 is one of A or V and X 5 is one of V or W;
  • X-LX2X 3 KX 4 X 2 X5X3PX3X ⁇ (SEQ ID NO: 11), where X] is one or two of D, E, S, T or N, X2 is one or two of P, G or D, X 3 is one of G, A, V, L, I or Y, X is one of R, K or H and X 5 is one of S, T, C, M or R;
  • X,X 2 X 3 X 4 WX 4 WX 4 X 5 K (SEQ ID NO: 18), where X x is one to four chosen from A, P or R, X 2 is one or two aromatic amino acids (F, Y and W), X 3 is one of P or K, X 4 is one, two or none chosen from A, P, Y or W and X 5 is one to three chosen from R or P;
  • X 1 X 2 X 3 X 4 X ⁇ VX 5 X 4 RGX 4 X 5 X 4 X 1 X 3 X 1 (SEQ ID NO: 32), where X, is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X is one of C, S, M, D or A, X 4 is one of F, I, V, M or R and X 5 is one of A, I, S, M, D or R; and
  • KX,KX 2 FX 2 KMLMX 2 ALKKX 3 (SEQ ID NO: 39), where X, is a polar amino acid (C, S, T, M, N and Q); X 2 is one of A, L, S or K and X 3 is 1-17 amino acids chosen from G, A, V, L, I, P, F, S, T, K and H;
  • KWKX 2 X 1 X 1 X 2 X 2 X 1 X 2 X 2 X 1 X 1 X 2 X 2 IFHTALKPISS (SEQ ID NO: 46), where Xi is a hydrophobic amino acid and X 2 is a hydrophilic amino acid.
  • the invention provides isolated cationic peptides KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53) and KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54).
  • nucleic acid sequences encoding the cationic peptides of the invention include vectors including such polynucleotides and host cells containing the vectors.
  • the present invention provides novel cationic peptides, characterized by a group of generic formulas, which have ability to modulate (e.g., up- and/or down regulate) polynucleotide expression, thereby regulating sepsis and inflammatory responses and/or innate immunity.
  • Innate immunity refers to the natural ability of an organism to defend itself against invasions by pathogens.
  • Pathogens or microbes as used herein may include, but are not limited to bacteria, fungi, parasites and viruses.
  • Innate immunity is contrasted with acquired/adaptive immunity in which the organism develops a defensive mechanism based substantially on antibodies and/or immune lymphocytes that is characterized by specificity, amplifiability and self vs. non-self dsicrimination. With innate immunity, broad, nonspecific immunity is provided and there is no immunologic memory of prior exposure.
  • innate immunity includes immune responses that affect other diseases, such as cancer, inflammatory diseases, multiple sclerosis, various viral infections, and the like.
  • cationic peptide refers to a sequence of amino acids from about 5 to about 50 amino acids in length. In one aspect, the cationic peptide of the invention is from about 10 to about 35 amino acids in length. A peptide is "cationic" if it possesses sufficient positively charged amino acids to have a pKa greater than 9.0.
  • At least two of the amino acid residues of the cationic peptide will be positively charged, for example, lysine or arginine.
  • “Positively charged” refers to the side chains of the amino acid residues which have a net positive charge at pH 7.0.
  • Examples of naturally occurring cationic antimicrobial peptides which can be recombinantly produced according to the invention include defensins, cathelicidins, magainins, melittin, and cecropins, bactenecins, indolicidins, polyphemusins, tachyplesins, and analogs thereof.
  • cationic peptides molecules used as part of a non-specific defense mechanism against microorganisms. When isolated, these peptides are toxic to a wide variety of microorganisms, including bacteria, fungi, and certain enveloped viruses. While cationic peptides act against many pathogens, notable exceptions and varying degrees of toxicity exist. However this patent reveals additional cationic peptides with no toxicity towards microorganisms but an ability to protect against infections through stimulation of innate immunity, and this invention is not limited to cationic peptides with antimicrobial activity. In fact, many peptides useful in the present invention do not have antimicrobial activity.
  • Cationic peptides known in the art include for example, the human cathelicidin LL-37, and the bovine neutrophil peptide indolicidin and the bovine variant of bactenecin, Bac2A.
  • innate immunity the immune response is not dependent upon antigens.
  • the innate immunity process may include the production of secretory molecules and cellular components as set forth above.
  • the pathogens are recognized by receptors encoded in the germline. These Toll-like receptors have broad specificity and are capable of recognizing many pathogens.
  • cationic peptides When cationic peptides are present in the immune response, they aid in the host response to pathogens. This change in the immune response induces the release of chemokines, which promote the recruitment of immune cells to the site of infection.
  • Chemokines are a subgroup of immune factors that mediate chemotactic and other pro-inflammatory phenomena (See, Schall, 1991, Cytokine 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, ⁇ which have two N-terminal cysteines separated by a single amino acid (CxC) and ⁇ which have two adjacent cysteines at the N terminus (CC). RANTES, MlP-l ⁇ and MlP-l ⁇ are members of the ⁇ subgroup (reviewed by Horuk, R., 1994, Trends Pharmacol. Sci, 15:159-165; Murphy, P. M., 1994, Annu.
  • Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, Trends Pharmacol. Sci. 15:159-165; and Murphy, P. M., 1994, Annu. Rev. Immunol. 12:593- 633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding.
  • Examples demonstrating the promiscuity among ⁇ chemokine receptors include: CC CKR-1, which binds RANTES and MlP-l ⁇ (Neote et al., 1993, Cell 72: 415-425), CC CKR-4, which binds RANTES, MlP-l ⁇ , and MCP-1 (Power et al., 1995, J. Biol. Chem. 270:19495-19500), and CC CKR-5, which binds RANTES, MlP-l , and MlP-l ⁇ (Alkhatib et al., 1996, Science, in press and Dragic et al., 1996, Nature 381:667-674).
  • a receptor known as the Duffy antigen
  • the present invention provides the use of compounds including cationic peptides of the invention to reduce sepsis and inflammatory responses by acting directly on host cells.
  • a method of identification of a polynucleotide or polynucleotides that are regulated by one or more sepsis or inflammatory inducing agents is provided, where the regulation is altered by a cationic peptide.
  • sepsis or inflammatory inducing agents include, but are not limited to endotoxic lipopolysaccharide (LPS), lipoteichoic acid (LTA) and/or CpG DNA or intact bacteria or other bacterial components.
  • the identification is performed by contacting the polynucleotide or polynucleotides with the sepsis or inflammatory inducing agents and further contacting with a cationic peptide either simultaneously or immediately after.
  • the expression of the polynucleotide in the presence and absence of the cationic peptide is observed and a change in expression is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing agent and inhibited by a cationic peptide.
  • the invention provides a polynucleotide identified by the method.
  • polynucleotides will be useful in methods of screening for compounds that can block sepsis or inflammation by affecting the expression of the polynucleotide. Such an effect on expression may be either up regulation or down regulation of expression.
  • the present invention also presents a method of identifying enhancers of innate immunity. Additionally, the present invention provides compounds that are used or identified in the above methods.
  • Candidate compounds are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, and the like to produce structural analogs.
  • Candidate agents are also found among biomolecules including, but not limited to: peptides, peptidiomimetics, saccharides, fatty acids, steroids, purines, pyrimidines, polypeptides, polynucleotides, chemical compounds, derivatives, structural analogs or combinations thereof.
  • Incubating components of a screening assay includes conditions which allow contact between the test compound and the polynucleotides of interest. Contacting includes in solution and in solid phase, or in a cell.
  • the test compound may optionally be a combinatorial library for screening a plurality of compounds.
  • Compounds identified in the method of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a compound.
  • a cationic peptide is utilized to detect and locate a polynucleotide that is essential in the process of sepsis or inflammation. Once identified, a pattern of polynucleotide expression may be obtained by observing the expression in the presence and absence of the cationic peptide. The pattern obtained in the presence of the cationic peptide is then useful in identifying additional compounds that can inhibit expression of the polynucleotide and therefore block sepsis or inflammation. It is well known to one of skill in the art that non-peptidic chemicals and peptidomimetics can mimic the ability of peptides to bind to receptors and enzyme binding sites and thus can be used to block or stimulate biological reactions.
  • an additional compound of interest provides a pattern of polynucleotide expression similar to that of the expression in the presence of a cationic peptide
  • that compound is also useful in the modulation of sepsis or an innate immune response.
  • the cationic peptides of the invention which are known inhibitors of sepsis and inflammation and enhancers of innate immunity are useful as tools in the identification of additional compounds that inhibit sepsis and inflammation and enhance innate immunity.
  • peptides of the invention have a widespread ability to reduce the expression of polynucleotides regulated by LPS.
  • High levels of endotoxin in the blood are responsible for many of the symptoms seen during a serious infection or inflammation such as fever and an elevated white blood cell count.
  • Endotoxin is a component of the cell wall of Gram-negative bacteria and is a potent trigger of the pathophysiology of sepsis. The basic mechanisms of inflammation and sepsis are related.
  • polynucleotide arrays were utilized to determine the effect of cationic peptides on the transcriptional response of epithelial cells.
  • Example 2 similarly, shows that peptides of the invention are capable of neutralizing the stimulation of immune cells by Gram positive and Gram negative bacterial products.
  • pro-inflammatory polynucleotides are down-regulated by cationic peptides, as set forth in table 24 such as TLR1 (AI339155), TLR2 (T57791), TLR5 (N41021), TNF receptor-associated factor 2 (T55353), TNF receptor-associated factor 3 (AA504259), TNF receptor superfamily, member 12 (W71984), TNF receptor superfamily, member 17 (AA987627), small inducible cytokine subfamily B, member 6 (AI889554), IL-12R beta 2 (AA977194), IL-18 receptor 1 (AA482489), while anti-inflammatory polynucleotides are up-regulated by cationic peptides, as seen in table 25 such as IL-1 R antagonist homolog 1 (AI167887), IL-10 R beta (AA486393), TNF Receptor member IB (AA150416), TNF receptor member 5 (H98636), TNF receptor member l ib (AA1949
  • Example 4 it can be seen that the cationic peptides of the invention alter polynucleotide expression in macrophage and epithelial cells.
  • the results of this example show that pro-inflammatory polynucleotides are down-regulated by cationic peptides (Table 24) whereas anti-inflammatory polynucleotides are up-regulated by cationic peptides (Table 25).
  • the invention provides a method of identifying an agent that enhances innate immunity.
  • a host cell polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity is contacted with an agent of interest. Expression of the polynucleotide is determined, both in the presence and absence of the agent. The expression is compared and of the specific modulation of expression was indicative of an enhancement of innate immunity.
  • the agent does not stimulate a septic reaction as revealed by the lack of upregulation of the pro-inflammatory cytokine TNF- ⁇ .
  • the agent reduces or blocks the inflammatory or septic response.
  • the agent reduces the expression of TNF- ⁇ and/or interleukins including, but not limited to, IL-l ⁇ , IL-6, IL-12 p40, IL-12 p70, and IL-8.
  • the invention provides methods of direct polynucleotide regulation by cationic peptides and the use of compounds including cationic peptides to stimulate elements of innate immunity.
  • the invention provides a method of identification of a pattern of polynucleotide expression for identification of a compound that enhances innate immunity.
  • an initial detection of a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide is made.
  • the pattern resulting from polynucleotide expression in the presence of the peptide represents stimulation of innate immunity.
  • a pattern of polynucleotide expression is then detected in the presence of a test compound, where a resulting pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide is indicative of a compound that enhances innate immunity.
  • the invention provides compounds that are identified in the above methods.
  • the compound of the invention stimulates chemokine or chemokine receptor expression.
  • Chemokine or chemokine receptors may include, but are not limited to CXCR4, CXCR1, CXCR2, CCR2, CCR4, CCR5, CCR6, MIP-1 alpha, MDC, MIP-3 alpha, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, and RANTES.
  • the compound is a peptide, peptidomimetic, chemical compound, or a nucleic acid molecule.
  • the polynucleotide expression pattern includes expression of pro-inflammatory polynucleotides.
  • pro-inflammatory polynucleotides may include, but are not limited to, ring finger protein 10 (D87451), serine/threonine protein kinase MASK (AB040057), KIAA0912 protein (AB020719), KIAA0239 protein (D87076), RAP1, GTPase activating protein 1 (M64788), FEM-1- like death receptor binding protein (AB007856), cathepsin S (M90696), hypothetical protein FLJ20308 (AK000315), pim-1 oncogene (M54915), proteasome subunit beta type 5 (D29011), KIAA0239 protein (D87076), mucin 5 subtype B tracheobronchial (AJ001403), cAMP response element-binding protein CREBPa, integrin alpha M (J03925), Rho-associated kina
  • the polynucleotide expression pattern includes expression of cell surface receptors that may include but is not limited to retinoic acid receptor (X06614), G protein-coupled receptors (Z94155, X81892, U52219, U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (Z29575), interferon gamma receptor 2 (U05875), cytokine receptor-like factor 1 (AF059293), class I cytokine receptor (AF053004), coagulation factor II (thrombin) receptor-like 2 (U92971), leukemia inhibitory factor receptor (NM 002310), interferon gamma receptor 1 (AL050337).
  • cell surface receptors may include but is not limited to retinoic acid receptor (X06614), G protein-coupled receptors (Z94155, X81892, U52219, U22491, AF0152
  • cationic peptides can neutralize the host response to the signaling molecules of infectious agents as well as modify the transcriptional responses of host cells, mainly by down-regulating the pro- inflammatory response and/or up-regulating the anti-inflammatory response.
  • Example 5 shows that the cationic peptides can aid in the host response to pathogens by inducing the release of chemokines, which promote the recruitment of immune cells to the site of infection. The results are confirmed by an in vivo application to mice.
  • cationic peptides have a substantial influence on the host response to pathogens in that they assist in regulation of the host immune response by inducing selective pro-inflammatory responses that for example promote the recruitment of immune cells to the site of infection but not inducing potentially harmful pro-inflammatory cytokines. Sepsis appears to be caused in part by an overwhelming pro-inflammatory response to infectious agents. Cationic peptides aid the host in a "balanced" response to pathogens by inducing an anti- inflammatory response and suppressing certain potentially harmful pro-inflammatory responses.
  • Example 7 the activation of selected MAP kinases was examined, to study the basic mechanisms behind the effects of interaction of cationic peptides with cells.
  • Macrophages activate MEK/ERK kinases in response to bacterial infection.
  • MEK is a MAP kinase kinase that when activated, phosphorylates the downstream kinase ERK (extracellular regulated kinase), which then dimerizes and translocates to the nucleus where it activates transcription factors such as Elk-1 to modify polynucleotide expression.
  • MEK/ERK kinases have been shown to impair replication of Salmonella within macrophages.
  • the kinases include MAP kinase kinase 6 (H070920), MAP kinase kinase 5 (W69649), MAP kinase 7 (H39192), MAP kinase 12 (AI936909) and MAP kinase-activated protein kinase 3 (W68281).
  • the methods of the invention may be used in combination, to identify an agent with multiple characteristics, i.e. a peptide with anti- inflammatory/anti-sepsis activity, and the ability to enhance innate immunity, in part by inducing chemokines in vivo.
  • the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 55 as compared to a non-infected subject.
  • the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a polynucleotide expression of at least 2 polynucleotides in Table 56 or Table 57 as compared to a non-infected subject.
  • the state of infection is due to infectious agents or signaling molecules derived therefrom, such as, but not limited to, Gram negative bacteria and Gram positive bacteria, viral, fungal or parasitic agents.
  • the invention provides a polynucleotide expression pattern of a subject having a state of infection identified by the above method.
  • Example 10 demonstrates this aspect of the invention.
  • table 61 demonstrates that both MEK and the NADPH oxidase inhibitors can limit bacterial replication (infection of IFN- ⁇ -primed macrophages by S. typhimurium triggers a MEK kinase). This is an example of how bacterial survival can be impacted by changing host cell signaling molecules.
  • compounds are presented that inhibit stromal derived factor-1 (SDF-1) induced chemotaxis of T cells. .
  • Compounds are also presented which decrease expression of SDF-1 receptor.
  • Such compounds also may act as an antagonist or inhibitor of CXCR-4.
  • the invention provides a cationic peptide that is an antagonist of CXCR-4.
  • the invention provides a method of identifying a cationic peptide that is an antagonist of CXCR-4. The method includes contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis.
  • a decrease in chemotaxis in the presence of the test peptide is then indicative of a peptide that is an antagonist of CXCR-4.
  • Such compounds and methods are useful in therapeutic applications in HIV patients. These types of compounds and the utility thereof is demonstrated, for example, in Example 11 (see also Tables 62, 63). In that example, cationic peptides are shown to inhibit cell migration and therefore antiviral activity.
  • the invention provides an isolated cationic peptides having an amino acid sequence of the general formula (Formula A):
  • Examples of the peptides of the invention include, but are not limited to: LLCRIVPVIPWCK (SEQ ID NO: 5), LRCPIAPVIPVCKK (SEQ ID NO: 6), KSRIVPAIPVSLL (SEQ ID NO: 7), KKSPIAPAIPWSR (SEQ ID NO: 8), RRARIVPAIPVARR (SEQ ID NO: 9) and LSRIAPAIPWAKL (SEQ ID NO: 10).
  • the invention provides an isolated linear cationic peptide having an amino acid sequence of the general formula (Formula B): X,LX2X3KX 4 X 2 X5X3PX3X ⁇ (SEQ ID NO: 11), wherein X, is one or two of D, E, S, T or N, X2 is one or two of P, G or D, X 3 is one of G, A, V, L, I or Y, X 4 is one of R, K or H and X 5 is one of S, T, C, M or R.
  • Examples of the peptides of the invention include, but are not limited to: DLPAKRGSAPGST (SEQ ID NO: 12), SELPGLKHPCVPGS (SEQ ID NO: 13), TTLGPVKRDSIPGE (SEQ ID NO: 14), SLPIKHDRLPATS (SEQ ID NO: 15), ELPLKRGRVPVE (SEQ ID NO: 16) and NLPDLKKPRVPATS (SEQ ID NO: 17).
  • the invention provides an isolated linear cationic peptide having an amino acid sequence of the general formula (Formula C): X,X 2 X 3 X 4 WX 4 WX 4 X 5 K (SEQ ID NO: 18) (this formula includes CP12a and CP12d) , wherein Xi is one to four chosen from A, P or R, X 2 is one or two aromatic amino acids (F, Y and W), X 3 is one of P or K, X 4 is one, two or none chosen from A, P, Y or W and X 5 is one to three chosen from R or P.
  • peptides of the invention include, but are not limited to: RPRYPWWPWWPYRPRK (SEQ ID NO: 19), RRAWWKAWWARRK (SEQ ID NO: 20), RAPYWPWAWARPRK (SEQ ID NO: 21), RPAWKYWWPWPWPRRK (SEQ ID NO: 22), RAAFKWAWAWWRRK (SEQ ID NO: 23) and RRRWKWAWPRRK (SEQ ID NO: 24).
  • the invention provides an isolated hexadecameric cationic peptide having an amino acid sequence of the general formula (Formula D): X,X 2 X 3 X 4 X ⁇ VX 3 X 4 RGX 4 X 3 X 4 X,X 3 X ⁇ (SEQ ID NO: 25) wherein Xj is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X 3 is C, S, M, D or A and X 4 is F, I, V, M or R.
  • Formula (Formula D) X,X 2 X 3 X 4 X ⁇ VX 3 X 4 RGX 4 X 3 X 4 X,X 3 X ⁇ (SEQ ID NO: 25) wherein Xj is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R
  • Examples of the peptides of the invention include, but are not limited to: RRMCIKVCVRGVCRRKCRK (SEQ ID NO: 26), KRSCFKVSMRGVSRRRCK (SEQ ID NO: 27), KKDAIKKVDIRGMDMRRAR (SEQ ID NO: 28), RKMVKVDVRGIMIRKDRR (SEQ ID NO: 29), KQCVKVAMRGMALRRCK (SEQ ID NO: 30) and RREAIRRVAMRGRDMKRMRR (SEQ ID NO: 31).
  • the invention provides an isolated hexadecameric cationic peptide having an amino acid sequence of the general formula (Formula E): X ⁇ X 2 X3X 4 X ⁇ VX5X 4 RGX 4 X 5 X 4 X ⁇ X3X ⁇ (SEQ ID NO: 32), wherein X, is one or two of R or K, X 2 is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H), X • 3 3 is one of C, S, M, D or A, X is one of F, I, V, M or R and X 5 is one of A, I, S, M, D or R.
  • peptides of the invention include, but are not limited to: RTCVKRVAMRGIIRKRCR (SEQ ID NO: 33), KKQMMKRVDVRGISVKRKR (SEQ ID NO: 34), KESIKVIIRGMMVRMKK (SEQ ID NO: 35), RRDCRRVMVRGIDIKAK (SEQ ID NO: 36), KRTAIKKVSRRGMSVKARR (SEQ ID NO: 37) and RHCIRRVSMRGIIMRRCK (SEQ ID NO: 38).
  • the invention provides an isolated longer cationic peptide having an amino acid sequence of the general formula (Formula F): KX,KX 2 FX 2 KMLMX 2 ALKKX 3 (SEQ ID NO: 39), wherein X] is a polar amino acid (C, S, T, M, N and Q); X 2 is one of A, L, S or K and X 3 is 1-17 amino acids chosen from G, A, V, L, I, P, F, S, T, K and H.
  • Formula F Formula (Formula F): KX,KX 2 FX 2 KMLMX 2 ALKKX 3 (SEQ ID NO: 39), wherein X] is a polar amino acid (C, S, T, M, N and Q); X 2 is one of A, L, S or K and X 3 is 1-17 amino acids chosen from G, A, V, L, I, P, F, S, T, K and H.
  • Examples of the peptides of the invention include, but are not limited to: KCKLFKKMLMLALKKVLTTGLPALKLTK (SEQ ID NO: 40), KSKSFLKMLMKALKKVLTTGLPALIS (SEQ ID NO: 41), KTKKFAKMLMMALKKVVSTAKPLAILS (SEQ ID NO: 42), KMKSFAKMLMLALKKVLKVLTTALTLKAGLPS (SEQ ID NO: 43), KNKAFAKMLMKALKKVTTAAKPLTG (SEQ ID NO: 44) and KQKLFAKMLMSALKKKTLVTTPLAGK (SEQ ID NO: 45).
  • the invention provides an isolated longer cationic peptide having an amino acid sequence of the general formula (Formula G): KWKX 2 X 1 X 1 X2X 2 X 1 X 2 X 2 X 1 X 1 X 2 X 2 IFHTALKPISS (SEQ ID NO: 46), wherein X, is a hydrophobic amino acid and X 2 is a hydrophilic amino acid.
  • Examples of the peptides of the invention include, but are not limited to: KWKSFLRTFKSPVRTIFHTALKPISS (SEQ ID NO: 47), KWKSYAHTIMSPVRLIFHTALKPISS (SEQ ID NO: 48), KWKRGAHRFMKFLSTIFHTALKPISS (SEQ ID NO: 49), KWKKWAHSPRKVLTRIFHTALKPISS (SEQ ID NO: 50), KWKSLVMMFKKPARRIFHTALKPISS (SEQ ID NO: 51) and KWKHALMKAHMLWHMIFHTALKPISS (SEQ ID NO: 52).
  • the invention provides an isolated cationic peptide having an amino acid sequence of the formula: KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53) or KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54).
  • isolated refers to a peptide that is substantially free of other proteins, lipids, and nucleic acids (e.g., cellular components with which an in vtvo-produced peptide would naturally be associated).
  • nucleic acids e.g., cellular components with which an in vtvo-produced peptide would naturally be associated.
  • the peptide is at least 70%, 80%, or most preferably 90% pure by weight.
  • the invention also includes analogs, derivatives, conservative variations, and cationic peptide variants of the enumerated polypeptides, provided that the analog, derivative, conservative variation, or variant has a detectable activity in which it enhances innate immunity or has anti-inflammatory activity. It is not necessary that the analog, derivative, variation, or variant have activity identical to the activity of the peptide from which the analog, derivative, conservative variation, or variant is derived.
  • a cationic peptide “variant” is an peptide that is an altered form of a referenced cationic peptide.
  • the term “variant” includes a cationic peptide in which at least one amino acid of a reference peptide is substituted in an expression library.
  • the term “reference” peptide means any of the cationic peptides of the invention (e.g., as defined in the above formulas), from which a variant, derivative, analog, or conservative variation is derived. Included within the term “derivative” is a hybrid peptide that includes at least a portion of each of two cationic peptides (e.g., 30-80% of each of two cationic peptides).
  • peptides in which one or more amino acids are deleted from the sequence of a peptide enumerated herein, provided that the derivative has activity in which it enhances innate immunity or has anti-inflammatory activity. This can lead to the development of a smaller active molecule which would also have utility.
  • amino or carboxy terminal amino acids which may not be required for enhancing innate immunity or anti-inflammatory activity of a peptide can be removed.
  • additional derivatives can be produced by adding one or a few (e.g. , less than 5) amino acids to a cationic peptide without completely inhibiting the activity of the peptide.
  • C-terminal derivatives e.g.
  • Peptides of the invention include any analog, homolog, mutant, isomer or derivative of the peptides disclosed in the present invention, so long as the bioactivity as described herein remains. Also included is the reverse sequence of a peptide encompassed by the general formulas set forth above. Additionally, an amino acid of "D" configuration may be substituted with an amino acid of "L” configuration and vice versa. Alternatively the peptide may be cyclized chemically or by the addition of two or more cysteine residues within the sequence and oxidation to form disulphide bonds.
  • the invention also includes peptides that are conservative variations of those peptides exemplified herein.
  • conservative variation denotes a polypeptide in which at least one amino acid is replaced by another, biologically similar residue.
  • conservative variations include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like.
  • Neutral hydrophilic amino acids that can be substituted for one another include asparagine, glutamine, serine and threonine.
  • the term "conservative variation” also encompasses a peptide having a substituted amino acid in place of an unsubstituted parent amino acid.
  • Such substituted amino acids may include amino acids that have been methylated or amidated. Other substitutions will be known to those of skill in the art.
  • antibodies raised to a substituted polypeptide will also specifically bind the unsubstituted polypeptide.
  • Peptides of the invention can be synthesized by commonly used methods such as those that include t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise synthesis in which a single amino acid is added at each step starting from the C-terminus of the peptide (See, Coligan, et al., Current Protocols in Immunology, Wiley Interscience, 1991, Unit 9). Peptides of the invention can also be synthesized by the well known solid phase peptide synthesis methods such as those described by Merrifield, J. Am. Chem.
  • the peptides can be purified by such techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent. Lyophilization of appropriate fractions of the column eluate yield homogeneous peptide, which can then be characterized by standard techniques such as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption spectroscopy, molar rotation, or measuring solubility. If desired, the peptides can be quantitated by the solid phase Edman degradation.
  • the invention also includes isolated nucleic acids (e.g., DNA, cDNA, or RNA) encoding the peptides of the invention. Included are nucleic acids that encode analogs, mutants, conservative variations, and variants of the peptides described herein.
  • isolated refers to a nucleic acid that is substantially free of proteins, lipids, and other nucleic acids with which an in v/vo-produced nucleic acids naturally associated.
  • the nucleic acid is at least 70%, 80%, or preferably 90% pure by weight, and conventional methods for synthesizing nucleic acids in vitro can be used in lieu of in vivo methods.
  • nucleic acid refers to a polymer of deoxyribo-nucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger genetic construct (e.g. , by operably linking a promoter to a nucleic acid encoding a peptide of the invention).
  • Numerous genetic constructs e.g. , plasmids and other expression vectors are known in the art and can be used to produce the peptides of the invention in cell-free systems or prokaryotic or eukaryotic (e.g. , yeast, insect, or mammalian) cells.
  • DNA encoding the cationic peptides of the invention can be inserted into an "expression vector.”
  • expression vector refers to a genetic construct such as a plasmid, virus or other vehicle known in the art that can be engineered to contain a nucleic acid encoding a polypeptide of the invention.
  • Such expression vectors are preferably plasmids that contain a promoter sequence that facilitates transcription of the inserted genetic sequence in a host cell.
  • the expression vector typically contains an origin of replication, and a promoter, as well as polynucleotides that allow phenotypic selection of the transformed cells (e.g. , an antibiotic resistance polynucleotide).
  • a promoter as well as polynucleotides that allow phenotypic selection of the transformed cells (e.g. , an antibiotic resistance polynucleotide).
  • Various promoters including inducible and constitutive promoters, can be utilized in the invention.
  • the expression vector contains a replicon site and control sequences that are derived from a species compatible with the host cell.
  • Transformation or transfection of a recipient with a nucleic acid of the invention can be carried out using conventional techniques well known to those skilled in the art.
  • competent cells that are capable of DNA uptake can be prepared using the CaCl 2 , MgCl 2 or RbCl methods known in the art.
  • physical means such as electroporation or microinjection can be used. Electroporation allows transfer of a nucleic acid into a cell by high voltage electric impulse.
  • nucleic acids can be introduced into host cells by protoplast fusion, using methods well known in the art. Suitable methods for transforming eukaryotic cells, such as electroporation and lipofection, also are known.
  • Host cells or "Recipient cells” encompassed by of the invention are any cells in which the nucleic acids of the invention can be used to express the polypeptides of the invention.
  • the term also includes any progeny of a recipient or host cell.
  • Preferred recipient or host cells of the invention include E. coli, S. aureus and P. aeruginosa, although other Gram-negative and Gram-positive bacterial, fungal and mammalian cells and organisms known in the art can be utilized as long as the expression vectors contain an origin of replication to permit expression in the host.
  • the cationic peptide polynucleotide sequence used according to the method of the invention can be isolated from an organism or synthesized in the laboratory.
  • Specific DNA sequences encoding the cationic peptide of interest can be obtained by: 1) isolation of a double-stranded DNA sequence from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the cationic peptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a donor cell. In the latter case, a double- stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.
  • DNA sequences are frequently the method of choice when the entire sequence of amino acid residues of the desired peptide product is known.
  • the synthesis of a DNA sequence has the advantage of allowing the inco ⁇ oration of codons which are more likely to be recognized by a bacterial host, thereby permitting high level expression without difficulties in translation.
  • virtually any peptide can be synthesized, including those encoding natural cationic peptides, variants of the same, or synthetic peptides.
  • the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single stranded form (Jay, et al. Nuc. Acid Res., 11:2325, 1983).
  • the peptide of the invention can be administered parenterally by injection or by gradual infusion over time.
  • the peptide. can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
  • Preferred methods for delivery of the peptide include orally, by encapsulation in microspheres or proteinoids, by aerosol delivery to the lungs, or transdermally by iontophoresis or transdermal electroporation. Other methods of administration will be known to those skilled in the art.
  • Preparations for parenteral administration of a peptide of the invention include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, sodium acetate, sodium citrate, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • Polynucleotide arrays were utilized to determine the effect of cationic peptides on the transcriptional response of epithelial cells.
  • the A549 human epithelial cell line was maintained in DMEM (Gibco) supplemented with 10 % fetal bovine serum (FBS, Medicorp).
  • the A549 cells were plated in 100 mm tissue culture dishes at 2.5 x 10° cells/dish, cultured overnight and then incubated with 100 ng/ml E. coli OI 11:B4 LPS (Sigma), without (control) or with 50 ⁇ g/ml peptide or medium alone for 4 h.
  • the polynucleotide arrays used were the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 10 ⁇ g of total RNA and labeled with Cy3 or Cy5 labeled dUTP. The probes were purified and hybridized to printed glass slides overnight at 42 2 C and washed. After washing, the image was captured using a Perkin Elmer array scanner. The image processing software (Imapolynucleotide 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. A "homemade" program was used to remove background.
  • the image processing software (Imapolynucleotide 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. A "homemade" program was used to remove background.
  • the program calculates the bottom 10 % intensity for each subgrid and subtracts this for each grid. Analysis was performed with Genespring software (Redwood City, CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in Tables 1 and 2. These tables 2 reflect only those polynucleotides that demonstrated significant changes in expression of the 14,000 polynucleotides that were tested for altered expression. The data indicate that the peptides have a widespread ability to reduce the expression of polynucleotides that were induced by LPS.
  • the peptide, SEQ ID NO: 27 is shown to potently reduce the expression of many of the polynucleotides up-regulated by E. coli Olll:B4 LPS as studied by polynucleotide microarrays.
  • Peptide 50 ⁇ g/ml
  • LPS 0.1 ⁇ g/ml
  • LPS alone was incubated with the A549 cells for 4 h and the RNA was isolated.
  • Five ⁇ g total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the third column of Table 1.
  • the "Ratio: LPS/control” column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells.
  • the “Ratio: LPS+ ID 27/control” column refers to the intensity of polynucleotide expression in cells stimulated with LPS and peptide divided by unstimulated cells.
  • Table 1 Reduction, by peptide SEQ ID 27, of A549 human epithelial cell polynucleotide expression up-regulated by E.coli Olll:B4 LPS
  • the "Ratio: LPS/control” column refers to the intensity of polynucleotide expression in LPS-simulated cells divided by in the intensity of unstimulated cells.
  • the other columns refer to the intensity of polynucleotide expression in cells stimulated with LPS and peptide divided by unstimulated cells.
  • Table 2 Human A549 Epithelial Cell Polynucleotide Expression up-regulated by E.coli OI 11 :B4 LPS and reduced by Cationic Peptides
  • the cells from mouse bone marrow were cultured in 150-mm plates in Dulbecco's modified Eagle medium (DMEM; Life Technologies, Burlington, ON) supplemented with 20 % FBS (Sigma Chemical Co, St. Louis, MO) and 20 % L cell-conditioned medium as a source of M-CSF.
  • DMEM Dulbecco's modified Eagle medium
  • FBS Sigma Chemical Co, St. Louis, MO
  • L cell-conditioned medium as a source of M-CSF.
  • macrophages were 60-80 % confluent, they were deprived of L cell-conditioned medium for 14-16 h to render the cells quiescent and then were subjected to treatments with 100 ng/ml LPS or 100 ng/ml LPS + 20 ⁇ g/ml peptide for 24 hours.
  • the release of cytokines into the culture supernatant was determined by ELISA (R&D Systems, Minneapolis, MN).
  • RAW 264.7 cells were seeded in 24 well plates at a density of 10° cells per well in DMEM and A549 cells were seeded in 24 well plates at a density of IO 5 cells per well in DMEM and both were incubated at 37°C in 5 % CO 2 overnight.
  • DMEM was aspirated from cells grown overnight and replaced with fresh medium.
  • blood from volunteer human donors was collected (according to procedures accepted by UBC Clinical Research Ethics Board, certificate C00-0537) by venipuncture into tubes (Becton Dickinson, Franklin Lakes, NJ) containing 14.3 USP units heparin/ml blood.
  • the blood was mixed with LPS with or without peptide in polypropylene tubes at 37°C for 6 h.
  • the samples were centrifuged for 5 min at 2000 x g, the plasma was collected and then stored at -20°C until being analyzed for IL-8 by ELISA (R&D Systems).
  • LPS or other bacterial products were incubated with the cells for 6-24 hr at 37°C in 5 % CO2. S.
  • LPS and E. coli 0111:B4 LPS were purchased from Sigma.
  • the Limulus amoebocyte lysate assay (Sigma) was performed on LTA preparations to confirm that lots were not significantly contaminated by endotoxin. Endotoxin contamination was less than 1 ng/ml, a concentration that did not cause significant cytokine production in the RAW 264.7 cells.
  • Non-capped lipoarabinomannan (AraLAM ) was a gift from Dr. John T. Belisle of Colorado State University.
  • the AraLAM from Mycobacterium was filter sterilized and the endotoxin contamination was found to be 3.75 ng per 1.0 mg of LAM as determined by Limulus Amebocyte assay.
  • LPS addition or later where specifically described
  • cationic peptides were added at a range of concentrations.
  • the supernatants were removed and tested for cytokine production by ELISA (R&D Systems). All assays were performed at least three times with similar results.
  • sepsis was induced by intraperitoneal injection of 2 or 3 ⁇ g of E.
  • mice coli Ol l l:B4 LPS in phosphate-buffered saline (PBS; pH 7.2) into galactosamine-sensitized 8- to 10- week-old female CD-I or BALB/c mice.
  • PBS phosphate-buffered saline
  • 200 ⁇ g in lOO ⁇ l of sterile water was injected at separate intraperitoneal sites within 10 min of LPS injection.
  • CD-I mice were injected with 400 ⁇ g E. coli Oll l:B4 LPS and 10 min later peptide (200 ⁇ g) was introduced by intraperitoneal injection. Survival was monitored for 48 hours post injection.
  • a different peptide, S ⁇ Q ID NO: 3 did not reduce LPS-induced production of TNF- ⁇ in RAW macrophage cells, demonstrating that this is not a uniform and predictable property of cationic peptides.
  • Representative peptides from each Formula were also tested for their ability to affect TNF- ⁇ production stimulated by E. coli Ol l l:B4 LPS (Table 4). The peptides had a varied ability to reduce TNF- ⁇ production although many of them lowered TNF- ⁇ by at least 60%.
  • peptides S ⁇ Q ID NO: 1 and S ⁇ Q ID NO: 2 could also reduce the ability of bacterial products to stimulate the production of IL-8 by an epithelial cell line.
  • LPS is a known potent stimulus of IL-8 production by epithelial cells.
  • Peptide S ⁇ Q ID 2 also inhibited LPS-induced production of IL-8 in whole human blood (Table 4).
  • high concentrations of peptide S ⁇ Q ID NO: 1 50 to 100 ⁇ g/ml
  • actually resulted in increased levels of IL-8 Table 5
  • Cationic peptides were also able to lower the stimulation of macrophages by Gram-positive bacterial products such as Mycobacterium non-capped lipoarabinomannan (AraLAM) and S. aureus LTA.
  • Gram-positive bacterial products such as Mycobacterium non-capped lipoarabinomannan (AraLAM) and S. aureus LTA.
  • SEQ ID NO: 1 inhibited induction of TNF- ⁇ in RAW 264.7 cells by the Gram-positive bacterial products, LTA (Table 14) and to a lesser extent AraLAM (Table 15).
  • Another peptide, SEQ ID NO: 2 was also found to reduce LTA-induced TNF- ⁇ production by RAW 264.7 cells.
  • Table 3 Reduction by SEQ ID 1 of LPS induced TNF- ⁇ production in RAW 264.7 cells.
  • RAW 264.7 mouse macrophage cells were stimulated with 100 ng/ml S. typhimurium LPS, 100 ng/ml B. cepacia LPS and 100 ng/ml E. coli 0111:B4 LPS in the presence of the indicated concentrations of SEQ ID 1 for 6 hr.
  • concentrations of TNF- ⁇ released into the culture supernatants were determined by ELISA.
  • Table 4 Reduction by Cationic Peptides of E. coli LPS induced TNF- ⁇ production in RAW 264.7 cells.
  • RAW 264.7 mouse macrophage cells were stimulated with 100 ng/ml E. coli 0111:B4 LPS in the presence of the indicated concentrations of cationic peptides for 6 h.
  • the concentrations of TNF- ⁇ released into the culture supernatants were determined by ⁇ LISA.
  • Background levels of TNF- ⁇ production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF- ⁇ levels ranging from 0.037 - 0.192 ng/ml.
  • the data is from duplicate samples and presented as the mean of three experiments + standard deviation.
  • Table 5 Reduction by SEQ ID 1 of LPS induced IL-8 production in A549 cells.
  • A549 cells were stimulated with increasing concentrations of SEQ ID 1 in the presence of LPS (100 ng/ml E. coli Ol ll:B4) for 24 hours.
  • the concentration of IL-8 in the culture supernatants was determined by ELISA.
  • the background levels of IL-8 from cells alone was 0.172 ⁇ 0.029 ng/ml. The data is presented as the mean of three experiments + standard error.
  • Table 6 Reduction by SEQ ID 2 of E. coli LPS induced IL-8 production in A549 cells.
  • Human A549 epithelial cells were stimulated with increasing concentrations of SEQ ID 2 in the presence of LPS (100 ng/ml E. coli Olll:B4) for 24 hours.
  • the concentration of IL-8 in the culture supernatants was determined by ELISA. The data is presented as the mean of three experiments + standard error.
  • Table 7 Reduction by SEQ ID 2 of E. coli LPS induced IL-8 in human blood.
  • Whole human blood was stimulated with increasing concentrations of peptide and E.coli OI 11:B4 LPS for 4 hr.
  • the human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA. The data is presented as the average of 2 donors.
  • Table 8 Reduction by SEQ ID 1 of E. coli LPS induced TNF- ⁇ production in murine bone marrow macrophages.
  • BALB/c Mouse bone marrow- derived macrophages were cultured for either 6 h or 24 h with 100 ng/ml E. coli 0111:B4 LPS in the presence or absence of 20 ⁇ g/ml of peptide. The supernatant was collected and tested for levels of TNF- ⁇ by ELISA. The data represents the amount of TNF- ⁇ resulting from duplicate wells of bone marrow-derived macrophages incubated with LPS alone for 6 h (1.1 ⁇ 0.09 ng/ml) or 24 h (1.7 ⁇ 0.2 ng/ml). Background levels of TNF- ⁇ were 0.038 ⁇ 0.008 ng/ml for 6 h and 0.06 ⁇ 0.012 ng/ml for 24h.
  • Table 9 Inhibition of E. coli LPS-induced TNF- ⁇ production by delayed addition of SEQ ID 1 to A549 cells. Peptide (20 ⁇ g/ml) was added at increasing time points to wells already containing A549 human epithelial cells and 100 ng/ml E. coli 0111:B4 LPS. The supernatant was collected after 6 hours and tested for levels of TNF- ⁇ by ELISA. The data is presented as the mean of three experiments + standard error.
  • Table 10 Protection against lethal endotoxaemia in galactosamine- sensitized CD-I mice by SEQ ID 1.
  • CD-I mice (9 weeks-old) were sensitized to endotoxin by three intraperitoneal injections of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (3 ⁇ g in 0.1 ml PBS).
  • Peptide, SEQ ID 1, (200 ⁇ g/mouse 8mg/kg) was injected at a separate intraperitoneal site 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded.
  • Table 11 Protection against lethal endotoxaemia in galactosamine- sensitized CD-I mice by Cationic Peptides.
  • CD-I mice (9 weeks-old) were sensitized to endotoxin by intraperitoneal injection of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (2 ⁇ g in 0.1 ml PBS).
  • mice Protection against lethal endotoxaemia in galactosamine- sensitized BALB/c mice by Cationic Peptides.
  • BALB/c mice (8 weeks-old) were sensitized to endotoxin by intraperitoneal injection of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 011 B4 LPS (2 ⁇ g in 0.1 ml PBS).
  • mice were injected intraperitoneal with 400 ⁇ g E. coli 0111:B4 LPS.
  • Table 14 Peptide inhibition of TNF- ⁇ production induced by S. aureus
  • Mycobacterium non-capped lipoarabinomannan RAW 264.7 mouse macrophage cells were stimulated with 1 ⁇ g/ml AraLAM in the absence and presence of 20 ⁇ g/ml peptide or Polymyxin B. The supernatant was collected and tested for levels of TNF- ⁇ by ELISA. Background levels of TNF- ⁇ production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF- ⁇ levels ranging from 0.037 0.192 ng/ml. The data is presented as the mean inhibition of three or more experiments + standard error.
  • the potential toxicity of the peptides was measured in two ways. First, the Cytotoxicity Detection Kit (Roche) (Lactate dehydrogenase -LDH) Assay was used. It is a colorimetric assay for the quantification of cell death and cell lysis, based on the measurement of LDH activity released from the cytosol of damaged cells into the supernatant. LDH is a stable cytoplasmic enzyme present in all cells and it is released into the cell culture supernatant upon damage of the plasma membrane.
  • This assay is a colorimetric assay for the quantification of cell proliferation and cell viability, based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells (a non- radioactive alternative to the [ H] -thymidine inco ⁇ oration assay).
  • HBE cells were incubated with 100 ⁇ g of peptide for 24 hours, and then 10 ⁇ l/well Cell Proliferation Reagent WST-1 was added. The cells are incubated with the reagent and the plate is then measured with an ELISA plate reader, OD 4 0 nm.
  • Tables 16 and 17 demonstrate that most of the peptides are not toxic to the cells tested. However, four of the peptides from Formula F (SEQ ID NOS: 40, 41, 42 and 43) did induce membrane damage as measured by both assays.
  • Table 16 Toxicity of the Cationic Peptides as Measured by the LDH Release Assay.
  • Human HBE bronchial epithelial cells were incubated with 100 ⁇ g/ml peptide or Polymyxin B for 24 hours. LDH activity was assayed in the supernatant of the cell cultures. As a control for 100% LDH release, Triton X-100 was added. The data is presented as the mean ⁇ standard deviation. Only peptides SEQ ID 40,41,42 and 43 showed any significant toxicity.
  • Table 17 Toxicity of the Cationic Peptides as Measured by the WST-1 Assay. HBE cells were incubated with 100 ⁇ g/ml peptide or Polymyxin B for 24 hours and cell viability was tested. The data is presented as the mean ⁇ standard deviation. As a control for 100% LDH release, Triton X-100 was added. Only peptides SEQ ID 40,41,42 and 43 showed any significant toxicity.
  • RNA pellet was resuspended in RNase-free water containing RNase inhibitor (Ambion, Austin, TX).
  • the RNA was treated with DNasel (Clontech, Palo Alto, CA) for 1 h at 37°C.
  • termination mix 0.1 M EDTA [pH 8.0], 1 mg/ml glycogen
  • the samples were extracted once with phenol: chloroform: isoamyl alcohol (25:24:1), and once with chloroform.
  • the RNA was then precipitated by adding 2.5 volumes of 100% ethanol and 1/10 th volume sodium acetate, pH 5.2.
  • the RNA was resuspended in RNase-free water with RNase inhibitor (Ambion) and stored at -70°C.
  • RNA quality of the RNA was assessed by gel electrophoresis on a 1% agarose gel. Lack of genomic DNA contamination was assessed by using the isolated RNA as a template for PCR amplification with ⁇ -actin-specific primers (5'-GTCCCTGTATGCCTCTGGTC-3' (SEQ ID NO: 55) and 5'- GATGTCACGCACGATTTCC-3' (SEQ ID NO: 56)). Agarose gel electrophoresis and ethidium bromide staining confirmed the absence of an amplicon after 35 cycles.
  • Atlas cDNA Expression Arrays (Clontech, Palo Alto, CA), which consist of 588 selected mouse cDNAs spotted in duplicate on positively charged membranes were used for early polynucleotide array studies (Tables 18,19)._ 32 P-radiolabeled cDNA probes prepared from 5 ⁇ g total RNA were incubated with the arrays overnight at 71°C. The filters were washed extensively and then exposed to a phosphoimager screen (Molecular Dynamics, Sunnyvale, CA) for 3 days at 4°C. The image was captured using a Molecular Dynamics PSI phosphoimager. The hybridization signals were analyzed using Atlaslmage 1.0 Image Analysis software (Clontech) and Excel (Microsoft, Redmond, WA).
  • the intensities for each spot were corrected for background levels and normalized for differences in probe labeling using the average values for 5 polynucleotides observed to vary little between the stimulation conditions: ⁇ -actin, ubiquitin, ribosomal protein S29, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and Ca 2+ binding protein.
  • ⁇ -actin ubiquitin
  • ribosomal protein S29 ribosomal protein S29
  • GPDH glyceraldehyde-3-phosphate dehydrogenase
  • the next polynucleotide arrays used were the Resgen Human cDNA arrays (identification number for the genome is PRHU03-S3), which consist of 7,458 human cDNAs spotted in duplicate. Probes were prepared from 15-20 ⁇ g of total RNA and labeled with Cy3 labeled dUTP. The probes were purified and hybridized to printed glass slides overnight at 42 S C and washed. After washing, the image was captured using a Virtek slide reader.- The image processing software (Imagene 4.1, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. Normalization and analysis was performed with Genespring software (Redwood City, CA).
  • Intensity values were calculated by subtracting the mean background intensity from the mean intensity value determined by Imagene.
  • the intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment.
  • the relative changes seen with cells treated with peptide compared to control cells can be found in the Tables below.
  • the other polynucleotide arrays used were the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 10 ⁇ g of total RNA and labeled with Cy3 or Cy5 labeled dUTP. In these experiments, A549 epithelial cells were plated in 100 mm tissue culture dishes at 2.5 x 10° cells/dish. Total RNA was isolated using RN Aqueous (Ambion). DNA contamination was removed with DNA-free kit (Ambion). The probes prepared from total RNA were purified and hybridized to printed glass slides overnight at 42°C and washed.
  • the image processing software (Imagene 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. An "in house” program was used to remove background. The program calculates the bottom 10% intensity for each subgrid and subtracts this for each grid. Analysis was performed with Genespring software (Redwood City, CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in the Tables below.
  • RNA samples were incubated with 1 ⁇ l oligodT (500 ⁇ g/ml) and 1 ⁇ l mixed dNTP stock at 1 mM, in a 12 ⁇ l volume with DEPC treated water at 65°C for 5 min in a thermocycler.
  • PCR was performed with a thermal cycler by using 30-40 cycles consisting of 30s of denaturation at 94 °C, 30s of annealing at either 52 °C or 55 °C and 40s of extension at 72 °C.
  • the number of cycles of PCR was optimized to lie in the linear phase of the reaction for each primer and set of RNA samples.
  • a housekeeping polynucleotide ⁇ -actin was amplified in each experiment to evaluate extraction procedure and to estimate the amount of RNA.
  • the reaction product was visualized by electrophoresis and analyzed by densitometry, with relative starting RNA concentrations calculated with reference to ⁇ -actin amplification.
  • Table 18 demonstrates that SEQ ID NO: 1 treatment of RAW 264.7 cells up-regulated the expression of more than 30 different polynucleotides on small Atlas microarrays with selected known polynucleotides.
  • the polynucleotides up-regulated by peptide, SEQ ID NO: 1, were mainly from two categories: one that includes receptors (growth, chemokine, interleukin, interferon, hormone, neurotransmitter), cell surface antigens and cell adhesion and another one that includes cell-cell communication (growth factors, cytokines, chemokines, interleukin, interferons, hormones), cytoskeleton, motility, and protein turnover.
  • the specific polynucleotides up-regulated included those encoding chemokine MCP-3, the anti-inflammatory cytokine IL-10, macrophage colony stimulating factor, and receptors such as IL-1R-2 (a putative antagonist of productive IL-1 binding to IL-1R1), PDGF receptor B, NOTCH4, LIF receptor, LFA-1, TGF ⁇ receptor 1, G-CSF receptor, and IFN ⁇ receptor.
  • the peptide also up-regulated polynucleotides encoding several metalloproteinases, and inhibitors thereof, including the bone morphogenetic proteins BMP-1, BMP-2, BMP-8a, TIMP2 and TIMP3.
  • the peptide up-regulated specific transcription factors including JunD, and the YY and LIM-1 transcription factors, and kinases such as Etkl and Csk demonstrating its widespread effects. It was also discovered from the polynucleotide array studies that SEQ ID NO: 1 down- regulated at least 20 polynucleotides in RAW 264.7 macrophage cells (Table 19). The polynucleotides down-regulated by peptide included DNA repair proteins and several inflammatory mediators such as MlP-l ⁇ , oncostatin M and IL-12. A number of the effects of peptide on polynucleotide expression were confirmed by RT-PCR (Table 20).
  • the peptides, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 19, and SEQ ID NO: 1, and representative peptides from each of the formulas also altered the transcriptional responses in a human epithelial cell line using mid-sized microarrays (7835 polynucleotides).
  • SEQ ID NO: 1 The effect of SEQ ID NO: 1 on polynucleotide expression was compared in 2 human epithelial cell lines, A549 and HBE.
  • Polynucleotides related to the host immune response that were up-regulated by 2 peptides or more by a ratio of 2-fold more than unstimulated cells are described in Table 21.
  • Polynucleotides that were down-regulated by 2 peptides or more by a ratio of 2-fold more than unstimulated cells are described in Table 22.
  • Table 23 and Table 24 the human epithelial pro-inflammatory polynucleotides that are up- and down-regulated respectively are shown.
  • Table 25 and Table 26 the anti-inflammatory polynucleotides affected by cationic peptides are shown. The trend becomes clear that the cationic peptides up-regulate the anti-inflammatory response and down-regulate the pro-inflammatory response. It was very difficult to find a polynucleotide related to the anti-inflammatory response that was down-regulated (Table 26).
  • the pro- inflammatory polynucleotides upregulated by cationic peptides were mainly polynucleotides related to migration and adhesion.
  • all the cationic peptides affected several toll-like receptor (TLR) polynucleotides, which are very important in signaling the host response to infectious agents.
  • TLR toll-like receptor
  • An important anti-inflammatory polynucleotide that was up-regulated by all the peptides is the IL-10 receptor.
  • IL-10 is an important cytokine involved in regulating the pro-inflammatory cytokines.
  • Table 18 Polynucleotides up-regulated by peptide, SEQ ID NO: 1, treatment of RAW macrophage cells".
  • the cationic peptides at a concentration of 50 ⁇ g/ml were shown to potently induce the expression of several polynucleotides.
  • Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of unstimulated cells is shown in the third column.
  • the "Ratio Peptide: Unstimulated” column refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 19 Polynucleotides down-regulated by SEQ ID NO: 1 treatment of RAW macrophage cells 3 .
  • the cationic peptides at a concentration of 50 ⁇ g/ml were shown to reduce the expression of several polynucleotides.
  • Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of unstimulated cells is shown in the third column.
  • the "Ratio Peptide: Unstimulated” column refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. The array experiments were repeated 3 times with different cells and the average fold change is shown below. Polynucleotides with an approximately two fold or greater change in relative expression levels are presented.
  • Table 20 Polynucleotide Expression changes in response to peptide, SEQ ID NO: 1, could be confirmed by RT-PCR.
  • RAW 264.7 macrophage cells were incubated with 50 ⁇ g/ml of peptide or media only for 4 hours and total RNA isolated and subjected to semi-quantitative RT-PCR. Specific primer pairs for each polynucleotide were used for amplification of RNA. Amplification of ⁇ -actin was used as a positive control and for standardization. Densitometric analysis of RT-PCR products was used. The results refer to the relative fold change in polynucleotide expression of peptide treated cells compared to cells incubated with media alone. The data is presented as the mean ⁇ standard error of three experiments.
  • Table 21 Polynucleotides up-regulated by peptide treatment of A549 epithelial cells 3 .
  • the cationic peptides at concentrations of 50 ⁇ g/ml were shown to increase the expression of several polynucleotides.
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3.
  • the intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Unstimulated" columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 22 Polynucleotides down-regulated by peptide treatment of A549 epithelial cells".
  • the cationic peptides at concentrations of 50 ⁇ g/ml were shown to decrease the expression of several polynucleotides.
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3.
  • the intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 23 Pro-inflammatory polynucleotides up-regulated by peptide treatment of A549 cells.
  • the cationic peptides at concentrations of 50 ⁇ g/ml were shown to increase the expression of certain pro-inflammatory polynucleotides (data is a subset of Table 21).
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 24 Pro-inflammatory polynucleotides down-regulated by peptide treatment of A549 cells.
  • the cationic peptides at concentrations of 50 ⁇ g/ml were shown to decrease the expression of certain pro-inflammatory polynucleotides (data is a subset of Table 22).
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
  • Table 25 Anti-inflammatory polynucleotides up-regulated by peptide treatment of A549 cells.
  • the cationic peptides at concentrations of 50 ⁇ g/ml were shown to increase the expression of certain anti-inflammatory polynucleotides (data is a subset of Table 21).
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 26 Anti-inflammatory polynucleotides down-regulated by peptide treatment of A549 cells.
  • the cationic peptides at concentrations of 50 ⁇ g/ml were shown to increase the expression of certain anti-inflammatory polynucleotides (data is a subset of Table 21).
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHU03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
  • Table 27 Polynucleotides up-regulated by SEQ ID NO: 6, in primary human macrophages.
  • the peptide SEQ ID NO: 6 at a concentration of 50 ⁇ g/ml was shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human macrophages for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04).
  • PRHU04 Human Operon arrays
  • the intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio peptide treated : Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 28 Polynucleotides down-regulated by SEQ ID NO: 6, in primary human macrophages.
  • the peptide SEQ ID NO: 6 at a concentration of 50 ⁇ g/ml was shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human macrophages for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio of Peptide: Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 29 Polynucleotides up-regulated by SEQ ID NO: 1, in HBE cells.
  • the peptide SEQ ID NO: 1 at a concentration of 50 ⁇ g/ml was shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human HBE epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the second column.
  • the "Ratio Peptide: Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 30 Polynucleotides down-regulated by Peptide (50 ⁇ g/ml), SEQ ID NO: 1, in HBE cells.
  • the peptide SEQ ID NO: 1 at a concentration of 50 ⁇ g/ml was shown to decrease the expression of many polynucleotides.
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the third column.
  • the "Ratio Peptide: Control" columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 31 Up-regulation of Polynucleotide expression in A549 cells induced by Formula A Peptides.
  • the peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04).
  • the intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively.
  • the "ID#: Control" columns refer to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
  • Table 32 Up-regulation of Polynucleotide expression in A549 cells induced by Formula B Peptides The peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides. Peptide was incubated with the human A54 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively. The "ID#: Control" columns refer to the intensity of polynucleotide expression in pepti simulated cells divided by the intensity of unstimulated cells.
  • Table 33 Up-regulation of Polynucleotide expression in A549 cells induced by Formula C Peptides.
  • the peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human A54 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04).
  • the intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively.
  • the "ID#: Control" columns refer to the intensity of polynucleotide expression in pepti simulated cells divided by the intensity of unstimulated cells.
  • Table 34 Up-regulation of Polynucleotide expression in A549 cells induced by Formula D Peptides.
  • the peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human A54 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04).
  • the intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively.
  • the "ID#: Control" columns refer to the intensity of polynucleotide expression in pepti simulated cells divided by the intensity of unstimulated cells.
  • Table 35 Up-regulation of Polynucleotide expression in A549 cells induced by Formula E Peptides.
  • the peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human A5 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of
  • the "ID#: Control" columns refer to the intensity of polynucleotide expression in pept simulated cells divided by the intensity of unstimulated cells.
  • Table 36 Up-regulation of Polynucleotide expression in A549 cells induced by Formula F Peptides.
  • the peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides.
  • Peptide was incubated with the human A54 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04).
  • the intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively.
  • the "Ratio ID#: Control” columns refer to the intensity of polynucleotide expression i peptide-simulated cells divided by the intensity of unstimulated cells.
  • Table 37 Up-regulation of Polynucleotide expression in A549 cells induced by Formula G and additional Peptides. peptides at a concentration of 50 ⁇ g/ml were shown to increase the expression of many polynucleotides. Peptide was incubated with t human A549 epithelial cells for 4 h and the RNA was isolated, converted into labelled cDNA probes and hybridised to Human Opero arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labelli
  • the "Ratio ID#: Control” columns refer to the intensity of polynucleotide expressio peptide-simulated cells divided by the intensity of unstimulated cells. Accession numbers and gene designations are U00115, zinc fing protein; M91036, hemoglobin gamma G;K000070, hypothetical protein; AF055899, solute carrier family 27; AK001490, hypothetical protein; X97674, nuclear receptor coactivator 2; AB022847, unknown; AJ275986, transcription factor; D10495, protein kinase C, delt L36642, EphA7; M31166, pentaxin-related gene; AF176012, unknown; AF072756, A kinase anchor protein 4; NM_014439, IL-1 Superfamily z; AJ271351, putative transcriptional regulator; AK000576, hypothetical protein; AJ272265, secreted phosphoprotein 2; AL12
  • the murine macrophage cell line RAW 264.7, THP-1 cells (human monocytes), a human epithelial cell line (A549), human bronchial epithelial cells (16HBEol4), and whole human blood were used. HBE cells were grown in MEM with Earle's. THP-1 cells were grown and maintained in RPMI 1640 medium. The RAW and A549 cell lines were maintained in DMEM supplemented with 10% fetal calf serum.
  • the cells were seeded in 24 well plates at a density of IO 6 cells per well in DMEM (see above) and A549 cells were seeded in 24 well plates at a density of 10 cells per well in DMEM (see above) and both were incubated at 37°C in 5 % CO 2 overnight. DMEM was aspirated from cells grown overnight and replaced with fresh medium. After incubation of the cells with peptide, the release of chemokines into the culture supernatant was determined by ELISA (R&D Systems, Minneapolis, MN).
  • mice were purchased from Charles River Laboratories and housed in standard animal facilities. Age, sex and weight matched adult mice were anaesthetized with an intraperitoneal injection of Avertin (4.4 mM 2-2-2- tribromoethanol, 2.5% 2-methyl-2-butanol, in distilled water), using 200 ⁇ l per 10 g body weight. The instillation was performed using a non-surgical, intratracheal instillation method adapted from Ho and Furst 1973.
  • Avertin 4.4 mM 2-2-2- tribromoethanol, 2.5% 2-methyl-2-butanol, in distilled water
  • the anaesthetized mouse was placed with its upper teeth hooked over a wire at the top of a support frame with its jaw held open and a spring pushing the thorax forward to position the pharynx, larynx and trachea in a vertical straight line.
  • the airway was illuminated externally and an intubation catheter was inserted into the clearly illuminated tracheal lumen.
  • Twenty- ⁇ l of peptide suspension or sterile water was placed in a well at the proximal end of the catheter and gently instilled into the trachea with 200 ⁇ l of air. The animals were maintained in an upright position for 2 minutes after instillation to allow the fluid to drain into the respiratory tree.
  • mice were euthanaised by intraperitoneal injection of 300 mg/kg of pentobarbital.
  • the trachea was exposed; an intravenous catheter was passed into the proximal trachea and tied in place with suture thread.
  • Lavage was performed by introducing 0.75 ml sterile PBS into the lungs via the tracheal cannula and then after a few seconds, withdrawing the fluid. This was repeated 3 times with the same sample of PBS.
  • the lavage fluid was placed in a tube on ice and the total recovery volume per mouse was approximately 0.5 ml.
  • the bronchoalveolar lavage (BAL) fluid was centrifuged at 1200 rpm for 10 min, the clear supernatant removed and tested for TNF- ⁇ and MCP-1 by ELISA.
  • the up-regulation of chemokines by cationic peptides was confirmed in several different systems.
  • the murine MCP-1 a homologue of the human MCP-1, is a member of the ⁇ (C-C) chemokine family. MCP-1 has been demonstrated to recruit monocytes, NK cells and some T lymphocytes.
  • SEQ ID NO: 1 When RAW 264.7 macrophage cells and whole human blood from 3 donors were stimulated with increasing concentrations of peptide, SEQ ID NO: 1, they produced significant levels of MCP-1 in their supernatant, as judged by ELISA (Table 36).
  • mice were given SEQ ID NO: 1 or endotoxin-free water by intratracheal instillation and the levels of MCP-1 and TNF- ⁇ examined in the bronchioalveolar lavage fluid after 3-4 hr. It was found that the mice treated with 50 ⁇ g/ml peptide, SEQ ID NO: 1 produced significantly increased levels of MCP-1 over mice given water or anesthetic alone (Table 42).
  • peptide, SEQ ID NO: 1 This was not a pro-inflammatory response to peptide, SEQ ID NO: 1 since peptide did not significantly induce more TNF- ⁇ than mice given water or anesthetic alone, peptide, SEQ ID NO: 1 was also found not to significantly induce TNF- ⁇ production by RAW 264.7 cells and bone marrow-derived macrophages treated with peptide, SEQ ID NO: 1 (up to 100 ⁇ g/ml) (Table 43). Thus, peptide, SEQ ID NO: 1 selectively induces the production of chemokines without inducing the production of inflammatory mediators such as TNF- ⁇ . This illustrates the dual role of peptide, SEQ ID NO: 1 as a factor that can block bacterial product-induced inflammation while helping to recruit phagocytes that can clear infections.
  • Table 38 Induction of MCP-1 in RAW 264.7 cells and whole human blood.
  • RAW 264.7 mouse macrophage cells or whole human blood were stimulated with increasing concentrations of LL-37 for 4 hr.
  • the human blood samples were centrifuged and the serum was removed and tested for MCP-1 by ELISA along with the supernatants from the RAW 264.7 cells.
  • the RAW cell data presented is the mean of three or more experiments ⁇ standard error and the human blood data represents the mean ⁇ standard error from three separate donors.
  • Table 39 Induction of IL-8 in A549 cells and whole human blood.
  • A549 cells or whole human blood were stimulated with increasing concentrations of peptide for 24 and 4 hr respectively.
  • the human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA along with the supernatants from the A549 cells.
  • the A549 cell data presented is the mean of three or more experiments ⁇ standard error and the human blood data represents the mean ⁇ standard error from three separate donors.
  • Table 40 Induction of IL-8 in A549 cells by Cationic peptides.
  • A549 human epithelial cells were stimulated with 10 ⁇ g of peptide for 24 hr. The supernatant was removed and tested for IL-8 by ELISA.
  • Table 41 Induction by Peptide of IL-8 in human blood. Whole human blood was stimulated with increasing concentrations of peptide for 4 hr . The human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA. The data shown is the average 2 donors.
  • Table 42 Induction of IL-8 in HBE cells. Increasing concentrations of the peptide were incubated with HBE cells for 8 h, the supernantant removed and tested for IL-8. The data is presented as the mean of three or more experiments + standard error.
  • Table 43 Induction of IL-8 in undifferentiated THP-1 cells.
  • the human monocyte THP-1 cells were incubated with indicated concentrations of peptide for 8 hr. The supernatant was removed and tested for IL-8 by ELISA.
  • Table 44 Induction of MCP-1 by Peptide, SEQ ID NO: 1 in mouse airway.
  • BALB/c mice were anaesthetised with avertin and given intratracheal instillation of peptide or water or no instillation (no treatment). The mice were monitored for 4 hours, anaesthetised and the BAL fluid was isolated and analyzed for MCP-1 and TNF- ⁇ concentrations by ELISA. The data shown is the mean of 4 or 5 mice for each condition + standard error.
  • Table 45 Lack of Significant TNF- ⁇ induction by the Cationic Peptides.
  • RAW 264.7 macrophage cells were incubated with indicated peptides (40 ⁇ g/ml) for 6 hours. The supernatant was collected and tested for levels of TNF- ⁇ by ELISA. The data is presented as the mean of three or more experiments + standard error.
  • the polynucleotide array data suggested that some peptides up-regulate the expression of the chemokine receptors IL-8RB, CXCR-4 and CCR2 by 10, 4 and 1.4 fold above unstimulated cells respectively.
  • the surface expression was examined by flow cytometry of these receptors on RAW cells stimulated with peptide for 4 hr.
  • Table 46 Increased surface expression of CXCR-4, IL-8RB and CCR2 in response to peptides.
  • RAW macrophage cells were stimulated with peptide for 4 hr. The cells were washed and stained with the appropriate primary and FITC-labeled secondary antibodies. The data shown represents the average (fold change of RAW cells stimulated with peptide from media) + standard error.
  • the cells were seeded at 2.5xl0 5 - 5 x 10 5 cells/ml and left overnight. They were washed once in media, serum starved in the morning (serum free media - 4hrs). The media was removed and replaced with PBS, then sat at 37°C for 15 minutes and then brought to room temp for 15 minutes. Peptide was added (concentrations 0. lug/ml - 50ug/ml) or H 2 O and incubated 10 min. The PBS was very quickly removed and replaced with ice-cold radioimmunoprecipitation (RIP A) buffer with inhibitors (NaF, B-glycerophosphate, MOL, Vanadate, PMSF, Leupeptin Aprotinin).
  • RIP A radioimmunoprecipitation
  • THP-1 cells were shaken on ice for 10-15 min or until the cells were lysed and the lysates collected.
  • the procedure for THP-1 cells was slightly different; more cells (2x10 ) were used. They were serum starved overnight, and to stop the reaction 1ml of ice-cold PBS was added then they sat on ice 5-10 min, were spun down then resuspended in RIPA. Protein concentrations were determined using a protein assay (Pierce, Rockford, IL.). Cell lysates (20 ⁇ g of protein) were separated by SDS-PAGE and transferred to nitrocellulose filters.
  • the filters were blocked for 1 h with 10 mM Tris-HCl, pH 7.5, 150 mM NaCl (TBS)/5% skim milk powder and then incubated overnight in the cold with primary antibody in TBS/0.05% Tween 20. After washing for 30 min with TBS/0.05% Tween 20, the filters were incubated for 1 h at room temperature with 1 ⁇ g/ml secondary antibody in TBS. The filters were washed for 30 min with TBS/0.05% Tween 20 and then incubated 1 h at room temperature with horseradish peroxidase-conjugated sheep anti-mouse IgG (1:10,000 in TBS/0.05% Tween 20).
  • peripheral blood mononuclear cells The peripheral blood (50-100ml) was collected from all subjects. Mononuclear cells were isolated from the peripheral blood by density gradient centrifugation on Ficoll-Hypaque. Inte ⁇ hase cells (mononuclear cells) were recovered, washed and then resuspended in recommended primary medium for cell culture (RPMI-1640) with 10% fetal calf serum (FCS) and 1% L-glutamine.
  • RPMI-1640 recommended primary medium for cell culture
  • FCS fetal calf serum
  • the gels were blotted onto nitrocellulose, blocked for 1 hour with 5% skim milk powder in Tris buffered saline (TBS) with 1% Triton X 100. Phosphorylation was detected with phosphorylation-specific antibodies.
  • SEQ ID NO: 2 was found to cause dose dependent phosphorylation of p38 and ERKl/2 in the mouse macrophage RAW cell line and the HBE cells.
  • SEQ ID NO: 3 caused phosphorylation of MAP kinases in THP-1 human monocyte cell line and phosphorylation of ERKl/2 in the mouse RAW cell line.
  • Table 47 Phosphorylation of MAP kinases in response to peptides.
  • Table 48 Peptide Phosphorylation of MAP kinases in human blood monocytes. SEQ ID NO: 1 at 50 ⁇ g/ml) was used to promote phosphorylation.
  • mice were given lx 10 s Salmonella and cationic peptide (200 ⁇ g) by intraperitoneal injection. The mice were monitored for 24 hours at which point they were euthanized, the spleen removed, homogenized and resuspended in PBS and plated on Luria Broth agar plates with Kanamycin (50 ⁇ g/ml). The plates were incubated overnight at 37 ° C and counted for viable bacteria (Table 49 and 50). CD-I mice were given 1 x 10 S. aureus in 5 % porcine mucin and cationic peptide (200 ⁇ g) by intraperitoneal injection (Table 51).
  • mice were monitored for 3 days at which point they were euthanized, blood removed and plated for viable counts.
  • CD-I male mice were given 5.8 x 10° CFU EHEC bacteria and cationic peptide (200 ⁇ g) by intraperitoneal (IP) injection and monitored for 3 days (Table 52).
  • IP intraperitoneal
  • a subset of the peptides demonstrated protection against infections.
  • the most protective peptides in the Salmonella model demonstrated an ability to induce a common subset of genes in epithelial cells (Table 53) when comparing the protection assay results in Tables 50 and 51 to the gene expression results in Tables 31-37. This clearly indicates that there is a pattern of gene expression that is consistent with the ability of a peptide to demonstrate protection.
  • Table 50 Effect of Cationic Peptides on Salmonella Infection in BALB/c mice.
  • the BALB/c mice were injected intraperitoneally with Salmonella and Peptide, and 24 h later the animals were euthanized, the spleen removed, homogenized, diluted in PBS and plate counts were done to determine bacteria viability.
  • Table 51 Effect of Cationic Peptides in a Murine S. aureus infection model.
  • CD-I mice were given 1 x 10 bacteria in 5 % porcine mucin via intraperitoneal (IP) injection.
  • Cationic peptide 200 ⁇ g was given via a separate IP injection. The mice were monitored for 3 days at which point they were euthanized, blood removed and plated for viable counts. The following peptides were not effective in controlling S. aureus infection: SEQ ID NO: 48, SEQ ID NO: 26
  • Table 53 Up-regulation of patterns of gene expression in A549 epithelial cells induced by peptides that are active in vivo.
  • the peptides SEQ ID NO: 30, SEQ ID NO: 7 and SEQ ID NO: 13 at concentrations of 50 ⁇ g/ml were each shown to increase the expression of a pattern of genes after 4 h treatment.
  • Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labelled cDNA probes and hybridised to Human Operon arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second columns for labelling of cDNA (average of Cy3 and Cy5).
  • the Fold Up regulation column refers to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
  • the SEQ ID NO: 37 peptide was included as a negative control that was not active in the murine infection models.
  • Table 54 Most cationic peptides studied here and especially the cationic peptides effective in infection models are not significantly antimicrobial. A dilution series of peptide was incubated with the indicated bacteria overnight in a 96-well plate. The lowest concentration of peptide that killed the bacteria was used as the MIC. The symbol > indicates the MIC is too large to measure. An MIC of 8 ⁇ g/ml or less was considered clinically meaningful activity.
  • S. typhimurium LPS and E. coli 0111 :B4 LPS were purchased from Sigma Chemical Co. (St. Louis, MO).
  • LTA Sigma
  • S. aureus was resuspended in endotoxin free water (Sigma).
  • the Limulus amoebocyte lysate assay was performed on LTA preparations to confirm that lots were not significantly contaminated by endotoxin (i.e. ⁇ 1 ng/ml, a concentration that did not cause significant cytokine production in the RAW cell assay).
  • the CpG oligodeoxynucleotides were synthesized with an Applied Biosystems Inc., Model 392 DNA/RNA Synthesizer, Mississauga, ON., then purified and resuspended in endotoxin-free water (Sigma). The following sequences were used CpG: 5'- TCATGACGTTCCTGACGTT-3' (SEQ ID NO: 57) and nonCpG: 5'- TTCAGGACTTTCCTCAGGTT-3' (SEQ ID NO: 58). The nonCpG oligo was tested for its ability to stimulate production of cytokines and was found to cause no significant production of TNF- ⁇ or IL-6 and therefore was considered as a negative control.
  • RNA was isolated from RAW 264.7 cells that had been incubated for 4h with medium alone, 100 ng/ml S. typhimurium LPS, 1 ⁇ g/ml S. aureus LTA, or 1 ⁇ M CpG (concentrations that led to optimal induction of tumor necrosis factor (TNF- ⁇ ) in RAW cells).
  • the RNA was used to polynucleotiderate cDNA probes that were hybridized to Clontech Atlas polynucleotide array filters, as described above. The hybridization of the cDNA probes to each immobilized DNA was visualized by autoradiography and quantified using a phosphorimager. Results from at least 2 to 3 independent experiments are summarized in Tables 55-59.
  • LPS treatment of RAW 264.7 cells resulted in increased expression of more than 60 polynucleotides including polynucleotides encoding inflammatory proteins such as IL-l ⁇ , inducible nitric oxide synthase (iNOS), MlP-l ⁇ , MlP-l ⁇ , MIP-2 ⁇ , CD40, and a variety of transcription factors.
  • inflammatory proteins such as IL-l ⁇ , inducible nitric oxide synthase (iNOS), MlP-l ⁇ , MlP-l ⁇ , MIP-2 ⁇ , CD40, and a variety of transcription factors.
  • LTA treatment differentially influenced expression of the largest subset of polynucleotides compared to LPS or CpG, including hyperstimulation of expression of Jun-D, Jun-B, Elk-1 and cyclins G2 and Al. There were only a few polynucleotides whose expression was altered more by LPS or CpG treatment.
  • Polynucleotides that had preferentially increased expression due to LPS treatment compared to LTA or CpG treatment included the cAMP response element DNA-binding protein 1 (CRE-BPI), interferon inducible protein 1 and CACCC Box-binding protein BKLF.
  • Polynucleotides that had preferentially increased expression after CpG treatment compared to LPS or LTA treatment included leukemia inhibitory factor (LIF) and protease nexin 1 (PN-1).
  • the other polynucleotide arrays used are the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 5 ⁇ g of total RNA and labeled with Cy3 or Cy5 labeled dUTP. In these experiments, A549 epithelial cells were plated in 100 mm tissue culture dishes at 2.5 x 10° cells/dish, incubated overnight and then stimulated with 100 ng/ml E. coli OI 11:B4 LPS for 4 h. Total RNA was isolated using RN Aqueous (Ambion). DNA contamination was removed with DNA-free kit (Ambion).
  • the probes prepared from total RNA were purified and hybridized to printed glass slides overnight at 42°C and washed. After washing, the image was captured using a Perkin Elmer array scanner.
  • the image processing software (Imapolynucleotide 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. An "in house” program was used to remove background. The program calculates the bottom 10 % intensity for each subgrid and subtracts this for each grid. Analysis was performed with Polynucleotidespring software (Redwood City, CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with LPS compared to control cells can be found in the Tables below. A number of previously unreported changes that would be useful in diagnosing infection are described in Table 60.
  • E. coli 0111:B4 LPS 100 ng/ml increased the expression of many polynucleotides in A549 cells as studied by polynucleotide microarrays. LPS was incubated with the A549 cells for 4 h and the RNA was isolated. 5 ⁇ g total RNA was used to make Cy3/Cy5 labelled cDNA probes and hybridised onto Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the second column of Table 55. The "Ratio: LPS/control" column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells.
  • E. coli Oll l:B4 LPS 100 ng/ml
  • E. coli Oll l:B4 LPS 100 ng/ml
  • LPS was incubated with the A549 cells for 4 h and the RNA was isolated. 5 ⁇ g total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto Human Operon arrays (PRHU04).
  • the intensity of unstimulated cells is shown in the second column of the Table.
  • the "Ratio: LPS/control" column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells.
  • Table 57 Polynucleotides expressed to similar extents after stimulation by the bacterial products LPS, LTA, and CpG DNA.
  • Bacterial products 100 ng/ml S. typhimurium LPS, 1 ⁇ g/ml S. aureus LTA or 1 ⁇ M CpG
  • Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of control, unstimulated cells is shown in the second column.
  • the "Ratio LPS/LTA/CpG: Control” column refers to the intensity of polynucleotide expression in bacterial product-simulated cells divided by the intensity of unstimulated cells.
  • Table 58 Polynucleotides that were differentially regulated by the bacterial products LPS, LTA, and CpG DNA.
  • Bacterial products 100 ng/ml S. typhimurium LPS, 1 ⁇ g/ml S. aureus LTA or 1 ⁇ M CpG
  • Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of control, unstimulated cells is shown in the second column.
  • the "Ratio LPS/LTA/CpG: Control” column refers to the intensity of polynucleotide expression in bacterial product-simulated cells divided by the intensity of unstimulated cells.
  • Table 59 Confirmation of Table 57 and 58 Array Data, a) Total RNA was isolated from unstimulated RAW macrophage cells and cells treated for 4 hr with 100 ng/ml S. typhimurium LPS, 1 ⁇ g/ml S. aureus LTA, 1 ⁇ M CpG DNA or media alone and Northern blots were performed the membrane was probed for GAPDH, CD14, vimentin, and tristetraprolin as described previously [Scott et al]. The hybridization intensities of the Northern blots were compared to GAPDH to look for inconsistencies in loading. These experiments were repeated at least three times and the data shown is the average relative levels of each condition compared to media (as measured by densitometry) + standard error.
  • RAW 264.7 cells were stimulated with 100 ng/ml S. typhimurium LPS, 1 ⁇ g/ml S. aureus LTA, 1 ⁇ M CpG DNA or media alone for 24 hours. Protein lysates were prepared, run on SDS PAGE gels and western blots were performed to detect LIF (R&D Systems) . These experiments were repeated at least three times and the data shown is the relative levels of LIF compared to media (as measured by densitometry) + standard error.
  • Supernatant was collected from RAW macrophage cells treated with 100 ng/ml S. typhimurium LPS, 1 ⁇ g/ml S.
  • aureus LTA 1 ⁇ M CpG DNA, or media alone for 24 hours and tested for the amount of NO formed in the supernatant as estimated from the accumulation of the stable NO metabolite nitrite with the Griess reagent as described previously [Scott, et al].
  • the data shown is the average of three experiments + standard error.
  • Table 60 Pattern of Gene expression in A549 Human Epithelial cells up-regulated by bacterial signalling molecules (LPS).
  • E. coli 0111:B4 LPS (100 ng/ml) increased the expression of many polynucleotides in A549 cells as studied by polynucleotide microarrays. LPS was incubated with the A549 cells for 4 h and the RNA was isolated. 5 ⁇ g total RNA was used to make Cy3/Cy5 labelled cDNA probes and hybridised onto Human Operon arrays (PRHU04). The examples of polynucleotide expression changes in LPS simulated cells represent a greater than 2- fold intensity level change of LPS treated cells from untreated cells.
  • the Salmonella Typhimurium strain SL1344 was obtained from the American Type Culture Collection (ATCC; Manassas, VA) and grown in Luria- Bertani (LB) broth.
  • ATCC American Type Culture Collection
  • LB Luria- Bertani
  • 10 ml LB in a 125 mL flask was inoculated from a frozen glycerol stock and cultured overnight with shaking at 37°C to stationary phase.
  • RAW 264.7 cells (lxlO 5 cells/well) were seeded in 24 well plates.
  • Bacteria were diluted in culture medium to give a nominal multiplicity of infection (MOI) of approximately 100, bacteria were centrifuged onto the monolayer at 1000 m for 10 minutes to synchronize infection, and the infection was allowed to proceed for 20 min in a 37°C, 5% C0 2 incubator. Cells were washed 3 times with PBS to remove extracellular bacteria and then incubated in DMEM + 10% FBS containing 100 ⁇ g/ml gentamicin (Sigma, St. Louis, MO) to kill any remaining extracellular bacteria and prevent re-infection. After 2 h, the gentamicin concentration was lowered to 10 ⁇ g/ml and maintained throughout the assay.
  • MOI multiplicity of infection
  • macrophages contained an average of 1 bacterium per cell as assessed by standard plate counts, which permitted analysis of macrophages at 24 h post-infection.
  • Bacterial filiamentation is related to bacterial stress. NADPH oxidase and iNOS can be activated by MEK/ERK signaling.
  • the results (Table 61) clearly demonstrate that the alteration of cell signaling is a method whereby intracellular Salmonella infections can be resolved. Thus since bacteria to up-regulate multiple genes in human cells, this strategy of blocking signaling represents a general method of therapy against infection.
  • Table 61 Effect of the Signaling Molecule MEK on Intracellular Bacteria in IFN- ⁇ -primed RAW cells.
  • SDF-1 a C-X-C chemokine is a natural ligand for HIV-1 coreceptor- CXCR4.
  • the chemokine receptors CXCR4 and CCR5 are considered to be potential targets for the inhibition of HIV-1 replication.
  • the crystal structure of SDF-1 exhibits antiparallel ⁇ -sheets and a positively charged surface, features that are critical in binding to the negatively charged extracellular loops of CXCR4.
  • the migration assays were performed as follows. Human Jurkat T cells were resuspended to 5 x 10° / ml in chemotaxis medium (RPMI 1640 / lOmM Hepes / 0.5 % BSA). Migration assays were performed in 24 well plates using 5 ⁇ m polycarbonate Transwell inserts (Costar). Briefly, peptide or controls were diluted in chemotaxis medium and placed in the lower chamber while 0.1 ml cells (5 x 10° / ml) was added to the upper chamber.
  • Table 63 Corresponding polynucleotide array data to Table 56:
  • Table 64 Corresponding FACs data to Tables 62 and 63:

Abstract

L'invention se rapporte à un procédé d'identification d'un polynucléotide ou d'un schéma de polynucléotides régulé par au moins un agent inducteur de sepsie ou d'inflammation et inhibé par un peptide. L'invention concerne un procédé d'identification d'un schéma d'expression de polynucléotide pour l'inhibition d'une réponse inflammatoire ou septique. Ce procédé consiste à mettre en contact des cellules avec LPS, LTA, CpG ADN et/ou des microbes intacts ou des composants microbiens en présence ou en l'absence d'un peptide ; à détecter un schéma d'expression de polynucléotide pour les cellules en la présence ou en l'absence du peptide, le schéma en la présence du peptide représentant l'inhibition d'une réponse inflammatoire ou septique. L'invention porte aussi sur des composés et des agents identifiés par les procédés de l'invention. Dans un autre aspect, l'invention concerne également des procédés et des composés permettant d'améliorer l'immunité innée d'un sujet.
EP20020804139 2001-12-03 2002-12-02 Effecteurs d'immunite innee Ceased EP1470249A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
US336632P 2001-12-03
PCT/CA2002/001830 WO2003048383A2 (fr) 2001-12-03 2002-12-02 Effecteurs d'immunite innee

Publications (1)

Publication Number Publication Date
EP1470249A2 true EP1470249A2 (fr) 2004-10-27

Family

ID=23316965

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20020804139 Ceased EP1470249A2 (fr) 2001-12-03 2002-12-02 Effecteurs d'immunite innee

Country Status (12)

Country Link
EP (1) EP1470249A2 (fr)
JP (1) JP2005536985A (fr)
KR (1) KR20040077669A (fr)
CN (2) CN101215601A (fr)
AU (1) AU2002365675B2 (fr)
CA (1) CA2468907A1 (fr)
HK (1) HK1075677A1 (fr)
IL (1) IL162300A0 (fr)
NZ (2) NZ563261A (fr)
SG (1) SG159382A1 (fr)
WO (1) WO2003048383A2 (fr)
ZA (1) ZA200404919B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
JP2007505048A (ja) * 2003-09-12 2007-03-08 ザ ユニバーシティー オブ ブリティッシュ コロンビア 先天性免疫のエフェクターの決定方法
WO2006005190A1 (fr) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Procede de criblage destine a la protection contre l'infection microbienne
WO2006137444A1 (fr) * 2005-06-22 2006-12-28 Seikagaku Corporation Procédé d’élimination de la radioactivité du lipoarabinomannane et application de ce procédé
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
EP1931779A4 (fr) * 2005-10-04 2009-07-29 Inimex Pharmaceuticals Inc Nouveaux peptides destines au traitement et a la prevention de troubles lies a l'immunite, y compris au traitement et a la prevention de l'infection par modulation de l'immunite innee
US8343475B2 (en) 2006-08-21 2013-01-01 The University Of British Columbia Small cationic antimicrobial peptides
JP2010505395A (ja) * 2006-10-04 2010-02-25 イニメックス ファーマシューティカルズ インコーポレイテッド 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
US20100255481A1 (en) * 2007-10-30 2010-10-07 Olympus Corporation Method for detection of adenoma or cancer by genetic analysis
WO2010026489A1 (fr) * 2008-09-05 2010-03-11 The University Of British Columbia Modulateurs d'immunité innée
WO2010042534A1 (fr) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides et procédés d'utilisation
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
KR20230119130A (ko) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법
WO2023063994A1 (fr) * 2021-10-13 2023-04-20 Phenomune, LLC Méthodes de test pour la détermination du phénotype t2r et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03048383A2 *

Also Published As

Publication number Publication date
AU2002365675A1 (en) 2003-06-17
AU2002365675B2 (en) 2007-04-05
NZ533721A (en) 2007-12-21
CN100357324C (zh) 2007-12-26
IL162300A0 (en) 2005-11-20
HK1075677A1 (en) 2005-12-23
KR20040077669A (ko) 2004-09-06
WO2003048383A2 (fr) 2003-06-12
CA2468907A1 (fr) 2003-06-12
ZA200404919B (en) 2006-05-31
NZ563261A (en) 2008-08-29
SG159382A1 (en) 2010-03-30
CN101215601A (zh) 2008-07-09
WO2003048383A3 (fr) 2004-08-05
CN1615368A (zh) 2005-05-11
JP2005536985A (ja) 2005-12-08

Similar Documents

Publication Publication Date Title
US7507787B2 (en) Effectors of innate immunity
Hedges et al. γδ T cells respond directly to pathogen-associated molecular patterns
EP1470249A2 (fr) Effecteurs d'immunite innee
Vaidya et al. Toll-like receptors and innate antiviral responses
Schlottmann et al. Prolonged classical NF-κB activation prevents autophagy upon E. coli stimulation in vitro: a potential resolving mechanism of inflammation
Jaso-Friedmann et al. The non-specific cytotoxic cell receptor (NCCRP-1): molecular organization and signaling properties
WO2003062273A2 (fr) Traitement medical
US7687454B2 (en) Effectors of innate immunity determination
US20070190533A1 (en) Effectors of innate immunity
KR20070033314A (ko) 양이온성 펩티드를 사용한 선천 면역의 자극 방법
AU2007201885A1 (en) Effectors of innate immunity
EP3966232A1 (fr) Inhibiteurs du facteur 5 de régulation de l'interféron et leurs utilisations
JP2009500314A (ja) 遺伝子調節
EP1278535B1 (fr) Utilisations de tgap7 en vue de moduler l'activation de leucocytes
Huang et al. Novel C-type lectin mediated Non-specific cytotoxic cells killing activity through NCCRP-1 in Nile tilapia (Oreochromis niloticus)
Kunkel et al. The function of chemokines in health and disease
Natarajan Characterization of chemokine CCL19 in the duck (Anas platyrhynchos)
Bowdish et al. The Human Antimicrobial Peptide
Scott The contribution of cationic antimicrobial peptides to the host immune response to bacterial infection
BARTZ et al. Workshop K Innate Immunity
BARTZ et al. Workshop C Innate Immunity
Kata Genome-wide transcriptome analysis of dendritic cells in a model of acute and persistent infection
Conti CLR16. 2: The identification, characterization, and functional analysis of a novel regualtor of T cell activation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040705

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20060213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20091005